Log in

Relevant bibliographies by topics / Drug targets / Journal articles

To see the other types of publications on this topic, follow the link: Drug targets.

Journal articles on the topic 'Drug targets'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug targets.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

S, Yalcin. "Therapeutic Drug Targets for Covid-19." Virology & Immunology Journal 7, no. 3 (2023): 1–10. http://dx.doi.org/10.23880/vij-16000325.

Full text

Abstract:

COVID-19 pandemic is a respiratory disease that has spread in many countries worldwide and has become a significant health problem. Caused by the virus called SARS-CoV-2, this disease typically manifests with symptoms such as fever, cough, shortness of breath, fatigue, and muscle aches. Various approaches are used in the treatment of COVID-19, including antiviral drugs, respiratory support, anti-inflammatory drugs, and antibody therapies. Antiviral drugs like remdesivir, in particular, are used to alleviate the course of the disease and expedite the recovery process. Vaccination programs are a

APA, Harvard, Vancouver, ISO, and other styles

2

Jain, Bhushan, Utkarsh Raj, and Pritish Kumar Varadwaj. "Drug Target Interplay: A Network-based Analysis of Human Diseases and the Drug Targets." Current Topics in Medicinal Chemistry 18, no. 13 (2018): 1053–61. http://dx.doi.org/10.2174/1568026618666180719160922.

Full text

Abstract:

Screening and identifying a disease-specific novel drug target is the first step towards a rational drug designing approach. Due to the advent of high throughput data generation techniques, the protein search space has now exceeded 24,500 human protein coding genes, which encodes approximately 1804proteins. This work aims at mining out the relationship between target proteins, drugs, and diseases genes through a network-based systems biology approach. A network of all FDA approved drugs, along with their targets were utilized to construct the proposed Drug Target (DT) network. Further, the exp

APA, Harvard, Vancouver, ISO, and other styles

3

Gollnick, Julia, Nikoletta Zeschick, Julia Muth, et al. "Controlling Prescribing through “Preferred Drug” Targets—The Bavarian Experience." International Journal of Environmental Research and Public Health 21, no. 9 (2024): 1174. http://dx.doi.org/10.3390/ijerph21091174.

Full text

Abstract:

Background: The rising costs of drugs are putting health care systems under pressure. We report on the Bavarian Drug Agreement, which employs prescribing targets for preferred and generic drugs in ambulatory care. Under this agreement, providers are regularly profiled with individual feedback but also possible sanctions. We investigated the degree to which targets were being met (or not) and why failure occurred. Methods: We analysed prescribing data aggregated by practice for the quarter 1/2018. We chose eight specialisation groups and analysed their drug targets with a high prescribing volum

APA, Harvard, Vancouver, ISO, and other styles

4

Robert C. Goldman and Barbara E. Laughon. "Editorial [Tuberculosis Drugs and Drug Targets]." Infectious Disorders - Drug Targets 7, no. 2 (2007): 71–72. http://dx.doi.org/10.2174/187152607781001835.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

BROXTERMAN, H., and N. GEORGOPAPADAKOU. "Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations." Drug Resistance Updates 8, no. 4 (2005): 183–97. http://dx.doi.org/10.1016/j.drup.2005.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Ying, and L. Amzel. "Tuberculosis Drug Targets." Current Drug Targets 3, no. 2 (2002): 131–54. http://dx.doi.org/10.2174/1389450024605391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Drews, Jürgen, and Stefan Ryser. "Classic drug targets." Nature Biotechnology 15, no. 13 (1997): 1350. http://dx.doi.org/10.1038/nbt1297-1350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kaestner, Phillip, and Holger Bastians. "Mitotic drug targets." Journal of Cellular Biochemistry 111, no. 2 (2010): 258–65. http://dx.doi.org/10.1002/jcb.22721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zhou, Ying, Yintao Zhang, Xichen Lian, et al. "Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents." Nucleic Acids Research 50, no. D1 (2021): D1398—D1407. http://dx.doi.org/10.1093/nar/gkab953.

Full text

Abstract:

Abstract Drug discovery relies on the knowledge of not only drugs and targets, but also the comparative agents and targets. These include poor binders and non-binders for developing discovery tools, prodrugs for improved therapeutics, co-targets of therapeutic targets for multi-target strategies and off-target investigations, and the collective structure-activity and drug-likeness landscapes of enhanced drug feature. However, such valuable data are inadequately covered by the available databases. In this study, a major update of the Therapeutic Target Database, previously featured in NAR, was

APA, Harvard, Vancouver, ISO, and other styles

10

Zhou, Ying, Yintao Zhang, Xichen Lian, et al. "Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents." Nucleic Acids Research 50, no. D1 (2021): D1398—D1407. http://dx.doi.org/10.1093/nar/gkab953.

Full text

Abstract:

Abstract Drug discovery relies on the knowledge of not only drugs and targets, but also the comparative agents and targets. These include poor binders and non-binders for developing discovery tools, prodrugs for improved therapeutics, co-targets of therapeutic targets for multi-target strategies and off-target investigations, and the collective structure-activity and drug-likeness landscapes of enhanced drug feature. However, such valuable data are inadequately covered by the available databases. In this study, a major update of the Therapeutic Target Database, previously featured in NAR, was

APA, Harvard, Vancouver, ISO, and other styles

11

Docherty, Andy J., Tom Crabbe, James P. O'Connell, and Colin R. Groom. "Proteases as drug targets." Biochemical Society Symposia 70 (September 1, 2003): 147–61. http://dx.doi.org/10.1042/bss0700147.

Full text

Abstract:

The effective management of AIDS with HIV protease inhibitors, or the use of angiotensin-converting enzyme inhibitors to treat hypertension, indicates that proteases do make good drug targets. On the other hand, matrix metalloproteinase (MMP) inhibitors from several companies have failed in both cancer and rheumatoid arthritis clinical trials. Mindful of the MMP inhibitor experience, this chapter explores how tractable proteases are as drug targets from a chemistry perspective. It examines the recent success of other classes of drug for the treatment of rheumatoid arthritis, and highlights the

APA, Harvard, Vancouver, ISO, and other styles

12

Wishart, David S., Craig Knox, An Chi Guo, et al. "DrugBank: a knowledgebase for drugs, drug actions and drug targets." Nucleic Acids Research 36, suppl_1 (2007): D901—D906. http://dx.doi.org/10.1093/nar/gkm958.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Cortes-Ciriano, Isidro, Alexios Koutsoukas, Olga Abian, Robert C. Glen, Adrian Velazquez-Campoy, and Andreas Bender. "Experimental validation of in silico target predictions on synergistic protein targets." MedChemComm 4, no. 1 (2013): 278–88. http://dx.doi.org/10.1039/c2md20286g.

Full text

Abstract:

Two relatively recent trends have become apparent in current early stage drug discovery settings: firstly, a revival of phenotypic screening strategies and secondly, the increasing acceptance that some drugs work by modulating multiple targets in parallel (‘multi-target drugs’).

APA, Harvard, Vancouver, ISO, and other styles

14

Feng, Yanghe, Qi Wang, and Tengjiao Wang. "Drug Target Protein-Protein Interaction Networks: A Systematic Perspective." BioMed Research International 2017 (2017): 1–13. http://dx.doi.org/10.1155/2017/1289259.

Full text

Abstract:

The identification and validation of drug targets are crucial in biomedical research and many studies have been conducted on analyzing drug target features for getting a better understanding on principles of their mechanisms. But most of them are based on either strong biological hypotheses or the chemical and physical properties of those targets separately. In this paper, we investigated three main ways to understand the functional biomolecules based on the topological features of drug targets. There are no significant differences between targets and common proteins in the protein-protein int

APA, Harvard, Vancouver, ISO, and other styles

15

Imming, Peter, Christian Sinning, and Achim Meyer. "Drugs, their targets and the nature and number of drug targets." Nature Reviews Drug Discovery 5, no. 10 (2006): 821–34. http://dx.doi.org/10.1038/nrd2132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lambert, Nzungize, Abualgasim Elgaili Abdalla, Xiangke Duan, and Jianping Xie. "Emerging drugs and drug targets against tuberculosis." Journal of Drug Targeting 25, no. 4 (2016): 296–306. http://dx.doi.org/10.1080/1061186x.2016.1258705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Pesce, E. R., I. L. Cockburn, J. L. Goble, L. L. Stephens, and G. L. Blatch. "Malaria Heat Shock Proteins: Drug Targets that Chaperone other Drug Targets." Infectious Disorders - Drug Targets 10, no. 3 (2010): 147–57. http://dx.doi.org/10.2174/187152610791163417.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ochoa, David, Andrew Hercules, Miguel Carmona, et al. "Open Targets Platform: supporting systematic drug–target identification and prioritisation." Nucleic Acids Research 49, no. D1 (2020): D1302—D1310. http://dx.doi.org/10.1093/nar/gkaa1027.

Full text

Abstract:

Abstract The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-

APA, Harvard, Vancouver, ISO, and other styles

19

Dai, Yan-Fen, and Xing-Ming Zhao. "A Survey on the Computational Approaches to Identify Drug Targets in the Postgenomic Era." BioMed Research International 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/239654.

Full text

Abstract:

Identifying drug targets plays essential roles in designing new drugs and combating diseases. Unfortunately, our current knowledge about drug targets is far from comprehensive. Screening drug targets in the lab is an expensive and time-consuming procedure. In the past decade, the accumulation of various types of omics data makes it possible to develop computational approaches to predict drug targets. In this paper, we make a survey on the recent progress being made on computational methodologies that have been developed to predict drug targets based on different kinds of omics data and drug pr

APA, Harvard, Vancouver, ISO, and other styles

20

Mi, Jie, Wenping Gong, and Xueqiong Wu. "Advances in Key Drug Target Identification and New Drug Development for Tuberculosis." BioMed Research International 2022 (February 25, 2022): 1–23. http://dx.doi.org/10.1155/2022/5099312.

Full text

Abstract:

Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug-resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti-TB drugs to treat drug-resistant TB and shorten the standard therapy. The discovery of targets of drug action will lay a theoretical foundation for new drug development. With the development of molecular biology and the success of Mtb genome sequencing, great progress has been made in the discovery of new targets and their relevant inhibitors. In this review, we summarized

APA, Harvard, Vancouver, ISO, and other styles

21

Zhang, Ying. "THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS." Annual Review of Pharmacology and Toxicology 45, no. 1 (2005): 529–64. http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.100120.

Full text

Abstract:

Modern chemotherapy has played a major role in our control of tuberculosis. Yet tuberculosis still remains a leading infectious disease worldwide, largely owing to persistence of tubercle bacillus and inadequacy of the current chemotherapy. The increasing emergence of drug-resistant tuberculosis along with the HIV pandemic threatens disease control and highlights both the need to understand how our current drugs work and the need to develop new and more effective drugs. This review provides a brief historical account of tuberculosis drugs, examines the problem of current chemotherapy, discusse

APA, Harvard, Vancouver, ISO, and other styles

22

Eze, S. C., M. Isioma, C. C. Ugorji, and G. O. Ozota. "Novel Antimalarial Drug Targets as Potent Tools to Accelerate Drug Discovery: A Short Review." Journal of Basic and Social Pharmacy Research 2, no. 5 (2022): 21–29. http://dx.doi.org/10.52968/27455385.

Full text

Abstract:

Introduction: Malaria is a significant tropical disease and the greatest killer of all time. The molecular pathways of known antimalarial drugs have been extensively elucidated. However, the emergence of resistant plasmodium species, especially that of P. falciparum, further threatens the prospects of its eradication. The advancement in proteomics and genomics has taken us a step further. Mere serendipity and pharmacology-based approaches can no longer take the lead in drug discovery. Newer and better antimalarial drug targets need to be sought. Objectives: This study presents the need and pro

APA, Harvard, Vancouver, ISO, and other styles

23

Schiffer, Celia. "Combatting Drug Resistance: Lessons from the viral proteases of HIV and HCV." Acta Crystallographica Section A Foundations and Advances 70, a1 (2014): C116. http://dx.doi.org/10.1107/s2053273314098830.

Full text

Abstract:

Drug resistance negatively impacts the lives of millions of patients and costs our society billions of dollars by limiting the longevity of many of our most potent drugs. Drug resistance can be caused by a change in the balance of molecular recognition events that selectively weakens inhibitor binding but maintains the biological function of the target. To reduce the likelihood of drug resistance, a detailed understanding of the target's function is necessary. Both structure at atomic resolution and evolutionarily constraints on its variation is required. "Resilient" targets are less susceptib

APA, Harvard, Vancouver, ISO, and other styles

24

Imming, Peter, Christian Sinning, and Achim Meyer. "Erratum: Drugs, their targets and the nature and number of drug targets." Nature Reviews Drug Discovery 6, no. 2 (2007): 168. http://dx.doi.org/10.1038/nrd2261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hu, Ye, and Jürgen Bajorath. "Monitoring drug promiscuity over time." F1000Research 3 (September 11, 2014): 218. http://dx.doi.org/10.12688/f1000research.5250.1.

Full text

Abstract:

Drug promiscuity and polypharmacology are much discussed topics in pharmaceutical research. Experimentally, promiscuity can be studied by profiling of compounds on arrays of targets. Computationally, promiscuity rates can be estimated by mining of compound activity data. In this study, we have assessed drug promiscuity over time by systematically collecting activity records for approved drugs. For 518 diverse drugs, promiscuity rates were determined over different time intervals. Significant differences between the number of reported drug targets and the promiscuity rates derived from activity

APA, Harvard, Vancouver, ISO, and other styles

26

Hu, Ye, and Jürgen Bajorath. "Monitoring drug promiscuity over time." F1000Research 3 (November 4, 2014): 218. http://dx.doi.org/10.12688/f1000research.5250.2.

Full text

Abstract:

Drug promiscuity and polypharmacology are much discussed topics in pharmaceutical research. Experimentally, promiscuity can be studied by profiling of compounds on arrays of targets. Computationally, promiscuity rates can be estimated by mining of compound activity data. In this study, we have assessed drug promiscuity over time by systematically collecting activity records for approved drugs. For 518 diverse drugs, promiscuity rates were determined over different time intervals. Significant differences between the number of reported drug targets and the promiscuity rates derived from activity

APA, Harvard, Vancouver, ISO, and other styles

27

Slogrove, Amy, Helena Rabie, and Mark Cotton. "Paediatric Antiretroviral Drug Targets." Infectious Disorders - Drug Targets 11, no. 2 (2011): 115–23. http://dx.doi.org/10.2174/187152611795589672.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Dubey, Abhishek, Antara Bagchi, Disha Sharma, Amit Dey, Kunal Nandy, and Rajaram Sharma. "Hepatic Capillariasis- Drug Targets." Infectious Disorders - Drug Targets 18, no. 1 (2018): 3–10. http://dx.doi.org/10.2174/1871526517666170427124254.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

P. Chakrabarty, S., H. Balaram, and S. Chandrasekaran. "Sirtuins: Multifaceted Drug Targets." Current Molecular Medicine 11, no. 9 (2011): 709–18. http://dx.doi.org/10.2174/156652411798062412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Dass, Crispin R. "Editorial: Bone Drug Targets." Current Drug Targets 19, no. 5 (2018): 408. http://dx.doi.org/10.2174/138945011905180319095631.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Krishnan, K., S. Campbell, F. Abdel-Rahman, S. Whaley, and W. Stone. "Cancer Chemoprevention Drug Targets." Current Drug Targets 4, no. 1 (2003): 45–54. http://dx.doi.org/10.2174/1389450033347028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Piccinini, Marco, Michael Mostert, and Maria Rinaudo. "Proteasomes as Drug Targets." Current Drug Targets 4, no. 8 (2003): 656–70. http://dx.doi.org/10.2174/1389450033490759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Saharan, V. D., S. Vijayaraghavan, and S. S. Mahajan. "DRUG TARGETS IN TUBERCULOSIS." INDIAN DRUGS 52, no. 12 (2015): 5–15. http://dx.doi.org/10.53879/id.52.12.10470.

Full text

Abstract:

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) and is the leading cause of morbidity and mortality among all infectious diseases. The emergence of resistant forms of tuberculosis, strong epidemiological coexistence of HIV, poor patient compliance due to extended chemotherapy and the associated side effects of the existing drugs highlight the fundamental need for new and more effective drugs to treat the disease. In this regard, the structural genomics of Mtb provides key information to identify potential targets for the design of newer antitubercul

APA, Harvard, Vancouver, ISO, and other styles

34

G??zey, Cuneyt, and Olav Spigset. "Genotyping of Drug Targets." Drug Safety 25, no. 8 (2002): 553–60. http://dx.doi.org/10.2165/00002018-200225080-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kolstoe, Simon E., and Steve P. Wood. "Drug targets for amyloidosis." Biochemical Society Transactions 38, no. 2 (2010): 466–70. http://dx.doi.org/10.1042/bst0380466.

Full text

Abstract:

The amyloid hypothesis indicates that protein misfolding is at the root of many neurodegenerative disorders. Small molecules targeting the formation, clearance, aggregation to toxic oligomers or SOD (superoxide dismutase)-like activities of Aβ (amyloid β-peptide) 1–42 have provided encouraging candidates for AD (Alzheimer's disease) medicines in animal models, although none have yet proved to be effective in human trials. We have been investigating approaches to treat systemic amyloidoses, conditions that show common features with some CNS (central nervous system) disorders. For TTR (transthyr

APA, Harvard, Vancouver, ISO, and other styles

36

Teicher, B. "Antibody-Drug Conjugate Targets." Current Cancer Drug Targets 9, no. 8 (2009): 982–1004. http://dx.doi.org/10.2174/156800909790192365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Benson, John D., Ying-Nan P. Chen, Susan A. Cornell-Kennon, et al. "Validating cancer drug targets." Nature 441, no. 7092 (2006): 451–56. http://dx.doi.org/10.1038/nature04873.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Crunkhorn, Sarah. "Identifying antimalarial drug targets." Nature Reviews Drug Discovery 18, no. 2 (2019): 98. http://dx.doi.org/10.1038/d41573-019-00009-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lehtiö, Lari, Nai-Wen Chi, and Stefan Krauss. "Tankyrases as drug targets." FEBS Journal 280, no. 15 (2013): 3576–93. http://dx.doi.org/10.1111/febs.12320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Canestrari, Emanuele, and Zain Paroo. "Ribonucleases as Drug Targets." Trends in Pharmacological Sciences 39, no. 10 (2018): 855–66. http://dx.doi.org/10.1016/j.tips.2018.07.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Chawla, Bhavna, and Rentala Madhubala. "Drug targets in Leishmania." Journal of Parasitic Diseases 34, no. 1 (2010): 1–13. http://dx.doi.org/10.1007/s12639-010-0006-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Burgen, A. S. V. "Targets of Drug Action." Annual Review of Pharmacology and Toxicology 40, no. 1 (2000): 1–16. http://dx.doi.org/10.1146/annurev.pharmtox.40.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Cully, Megan. "Drug development: Illuminated targets." Nature 511, no. 7508 (2014): S12—S13. http://dx.doi.org/10.1038/511s12a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Papavassiliou, Kostas A., and Athanasios G. Papavassiliou. "Transcription Factor Drug Targets." Journal of Cellular Biochemistry 117, no. 12 (2016): 2693–96. http://dx.doi.org/10.1002/jcb.25605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Williams, Michael. "Receptors as Drug Targets." Current Protocols in Pharmacology 00, no. 1 (1998): 1.1.1–1.1.17. http://dx.doi.org/10.1002/0471141755.ph0101s00.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Arenz, Christoph. "MicroRNAs—Future Drug Targets?" Angewandte Chemie International Edition 45, no. 31 (2006): 5048–50. http://dx.doi.org/10.1002/anie.200601537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Li, Zixi. "Review of Expected Drug Targets and Targeted Drug Treatments for Hepatitis B." Theoretical and Natural Science 99, no. 1 (2025): 221–27. https://doi.org/10.54254/2753-8818/2025.23532.

Full text

Abstract:

Chronic hepatitis B virus infection, which affecting over 300 million people globally, is strongly linked to hepatocellular carcinoma (HCC). HBV, partially double-stranded smal DNA virus, targets hepatocytes and will progress to liver cirrhosis and HCC. Although significant advancements have been made in antiviral therapy, a definitive cure remains elusive, primarily because of the persistence of covalently closed circular DNA (cccDNA). Significantly burdening patients and healthcare systems due to monitoring needs, drug resistance risks, and side effects. Current therapeutic options, includin

APA, Harvard, Vancouver, ISO, and other styles

48

Li, Ying Hong, Chun Yan Yu, Xiao Xu Li, et al. "Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics." Nucleic Acids Research 46, no. D1 (2017): D1121—D1127. http://dx.doi.org/10.1093/nar/gkx1076.

Full text

Abstract:

Abstract Extensive efforts have been directed at the discovery, investigation and clinical monitoring of targeted therapeutics. These efforts may be facilitated by the convenient access of the genetic, proteomic, interactive and other aspects of the therapeutic targets. Here, we describe an update of the Therapeutic target database (TTD) previously featured in NAR. This update includes: (i) 2000 drug resistance mutations in 83 targets and 104 target/drug regulatory genes, which are resistant to 228 drugs targeting 63 diseases (49 targets of 61 drugs with patient prevalence data); (ii) differen

APA, Harvard, Vancouver, ISO, and other styles

49

Escribá, Pablo V., Xavier Busquets, Silvia Terés, et al. "Lipids as clinical drugs, lipids as drug targets." Chemistry and Physics of Lipids 163 (August 2010): S8. http://dx.doi.org/10.1016/j.chemphyslip.2010.05.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Vasaikar, Suhas, Pooja Bhatia, Partap Bhatia, and Koon Chu Yaiw. "Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets." Biomedicines 4, no. 4 (2016): 27. http://dx.doi.org/10.3390/biomedicines4040027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!